瑞舒伐他汀与阿托伐他汀治疗非ST段抬高型急性心肌梗死患者对炎症因子及左室重构的影响被引量：29

Effects of rosuvastatin and atorvastatin on inflammatory factors and left ventricular remodeling in patients with non-ST segment elevation acute myocardial infarction

下载PDF

导出

摘要目的：探讨瑞舒伐他汀与阿托伐他汀治疗非ST段抬高型急性心肌梗死（NSTEMI）患者对炎症因子及左室重构的影响。方法：选择2013年1月～2014年12月我院收治的NSTEMI患者100例,随机分为观察组与对照组,各50例,两组均给予积极的心肌梗死综合治疗,同期对照组给予阿托伐他汀治疗,观察组给予瑞舒伐他汀治疗,比较两组治疗后血清炎症因子与左室重构相关指标。结果：观察组治疗1、3个月血清肿瘤坏死因子α（TNF-α）、白介素6（IL-6）、高敏C反应蛋白（hsCRP）水平均明显低于对照组（P〈0.05）,左室射血分数（LVEF）高于对照组,左室舒张末期直径（LVEDD）、左心室收缩末径（LVESD）、左室后壁厚度（PWT）低于对照组（P〈0.05）,血管紧张素Ⅱ（AngⅡ）、Ⅲ型前胶原肽（PⅢNP）、氨基末端脑钠肽前体（NT-proBNP）水平低于对照组（P〈0.05）。结论：瑞舒伐他汀在改善NSTEMI炎症因子水平,预防左室重构方面优于阿托伐他汀。 Objective：To explore the effects of rosuvastatin and atorvastatin on inflammatory factors and left ventricular remodeling in patients with non-ST segment elevation acute myocardial.Methods：A total of 100 cases patients of NSTEMI were selected that they were admitted during January 2013 to December 2014 and randomly divided into observer group and control group,50 cases in each group.Patients in two groups were given a comprehensive treatment of myocardial infarction,the control group was given the treatment of rosuvastatin and the observer group was given the treatment of atorvastatin over the same period,compared the related indicators of serum inflammatory factors and left ventricular remodeling after treatment in two groups.Results：The observer group serum TNF-α,IL-6,hs-CRP levels were significantly lower than the control group in the treatment of 1months,3months,The difference was statistically significant（P〈0.05）.The observer group was treated for 1months,3months LVEF higher than the control group,and LVEDD,LVESD,PWT lower than the control group,so the difference was statistically significant（P〈0.05）.The observer group was treated for 1months,3months AngⅡ,PⅢNP,NT-proBNP level was lower than the control group,therefore the difference was statistically significant（P〈0.05）.Conclusions：The rosuvastatin will be better than the atorvastatin in improving the level of NSTEMI inflammatory factors,prevention of left ventricular remodeling.

作者周云渠乐朱小莉

机构地区新疆医科大学附属中医医院心内四科新疆医科大学附属中医医院干部一科

出处《海南医学院学报》 CAS 2016年第13期1390-1393,共4页 Journal of Hainan Medical University

基金新疆维吾尔自治区省级攻关项目(2014991B219)~~

关键词瑞舒伐他汀阿托伐他汀非ST段抬高型急性心肌梗死(NSTEMI) 炎症因子左室重构 Rosuvastatin Atorvastatin Non-ST segment elevation myocardial infarction Inflammatory factors Left ventricular remodeling

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献20

1Yogo M,Sasaki M,Ayaori M,et al.Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression:Serial magnetic resonance imaging observations from RAPID study[J].Atherosclerosis,2014,232(1):31-39.
2Sinclair H,Bourantas C,Bagnall A,et al.OCT for the Identification of vulnerable plaque in acute coronary syndrome[J].JACC:Cardiovascular Imaging,2015,8(2):198-209.
3Wang W,Zhang Y,Gao M,et al.Effect of rosuvastatin on atrial structural remodeling in rabbits with myocardial infarction[J].Biomed Rep,2014,3(1):78-82.
4Liu Q,Wang T,Chen R,et al.Mean platelet volume predicts left descending artery occlusion in patients with non-ST-elevation myocardial infarction[J].Platelets,2014,25(4):246-251.
5急性心肌梗死诊断和治疗指南(摘登)[J].新医学,2006,37(1):46-46. 被引量：25
6Seker FB,Kilic U,Caglayan B,et al.HMG-CoA reductase inhibitor rosuvastatin improves a-bnormal brain electrical activity via mechanisms involving eNOS[J].Neuroscience,2014,19(284):349-359.
7Jones DA,Rathod KS,Gallagher S,et al.Manual thrombus aspiration is not associated with reduced mortality in patients treated with primary percutaneous coronary intervention:an observational study of 10,929patients with ST-Segment elevation myocardial infarction from the London Heart Attack Group[J].JACC,2015,8(4):575-584.
8王亚利,胡申江,王欢,毛萍,刘远伟,杜常青.不同剂量瑞舒伐他汀对急性冠脉综合征患者血清高敏C反应蛋白和基质金属蛋白酶-9的影响[J].中华危重症医学杂志（电子版）,2014,7(3):37-39. 被引量：16
9Liu Q,Wang T,Chen R,et al.Mean platelet volume predicts left descending artery occlusion in patients with non-ST-elevation myocardial infarction[J].Platelets, 2014,25(4):246-251.
10Stone NJ,Robinson JG,Lichtenstein AH,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(25):2889-2934.

二级参考文献35

1张捷,贾珂珂,胡晓舟,崔丽艳.血清NT-proBNP和CRP水平对AMI后左室重构的预测价值[J].临床检验杂志,2006,24(2):91-93. 被引量：17
2Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors [J]. Curr Med Chen. 2009, 16 (11): 1349-1354.
3American College of Cardiology, American Heart Asso- ciation. Guidelines of the American college of cardiology / American heart association 2007 for the management of patients with unstable angina/non-ST- elevation myocardial infarction. Part VI [J]. Kardiologiia, 2008, 48 (9): 66-86.
4Peisajovich A, Marnell L, Mold C, et al. C-reactive protein at the interface between innate immunity and inflammation [J]. Expert Rev Clin Immunol, 2008, 4 (3): 379-390.
5Siqueira DA, Sousa AG, Costa Junior Jde R, et al. Correlation between plaque composition as assessed by virtual histology and C-reactive protein [J]. Arq Bras Cardiol, 2013, 101 (1): 78-86.
6Fiotti N, Altamura N, Orlando C, et al. Metall-opro- teinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI [J]. Int J Cardiol, 2008, 127 (3): 350-357.
7Shi JZ, Wang LY, Zhu Y, et al. OX40 ligand levels and high-sensitivity C-reactive protein levels in blood from local coronary plaque and the femoral artery in patients with acute coronary syndrome or stable angina [J]. J Int Med Res, 2011, 39 (4): 1275-1283.
8Guzel S, Serin O, Guzel EC, et al. Interleukin-33, m- atrix metalloproteinase-9, and tissue inhibitor [corrected] of matrix metalloproteinase-1 in myocardial infarction[J]. Korean J Intern Med, 2013, 28 (2): 165-173.
9Rapezzi C, Biagini E, Branzi A. Guidelines for the d- iagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology[J]. Eur Heart J, 2008, 29 (2): 277-278.
10Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes normocholesterolemic animals[J]. 1004-1010. anglogenesxs m Nat Med, 2000, 6 (9):.